This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.

Provided herein are theranostic compositions comprising a Janus nanoparticle-coated microbubble that are useful for imaging (e.g., MRI, or ultrasound) and for delivering a therapeutic or bioactive agent (e.g., nucleic acid(s), drugs, etc), among other uses.

The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.

An ophthalmic drug delivery carrier includes a resveratrol-encapsulating poly(-caprolactone) (PCL) nanoparticle, metformin grafted on a surface of the resveratrol-encapsulating PCL nanoparticle, and a transacting activator of transcription (TAT) peptide grafted on the surface of the resveratrol-encapsulating PCL nanoparticle. A method for preparing the ophthalmic drug delivery carrier and a method for alleviating macular degeneration using the ophthalmic drug delivery carrier are also provided.

A polypeptide modified complex in the pharmaceutical field that can specifically adsorb apolipoproteins in plasma and can mediate a drug across the blood-brain barrier, a target delivery system, and use thereof in preparation of a formulation for diagnosing and treating brain tumors and other brain diseases. The polypeptide fragment (SP) of the amyloid (relating to one type) is modified shown that the modified delivery system increases uptake the of the amyloid by vascular endothelial cells after the modified delivery system forms a protein crown with plasma proteins. The modified liposome delivery system delivers a drug to the lesion site more effectively, significantly improving the therapeutic effect of the drug. After the SP adsorbs plasma proteins, a drug may be mediated across the blood-brain barrier and/or targeted to tumor neovascular and tumor cells, and the modified drug and delivery system thereof obtain a better therapeutic effect when treating brain tumors and other diseases in the brain.

The present invention provides, among other things, improved compositions comprising mRNA lipid nanoparticles and surfactants.

Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.

The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a neutrophil-associated disease or condition in a subject in need thereof are also provided.

Compositions and methods for targeted delivery of active agents to cells are provided. The compositions comprise a wholly or partially double-stranded synthetic DNA carrier, and an active agent intercalated in double-stranded portions of the DNA carrier. The DNA carrier may also be linked to a targeting agent. The compositions are useful for delivering an active agent into a targeted cell type, for example a cytotoxic agent.

The invention relates to novel polymer conjugated lipids and to novel compositions comprising said novel polymer conjugated lipids useful for the delivery of nucleic acids into living cells.